The evolution of topical medications: From corticosteroids to novel agents.

Molly Borucki*

Department of Dermatology, Brown University, USA

Introduction

Topical medications have long been a cornerstone in the treatment of various skin disorders, offering localized effects with minimal systemic exposure. Over the years, advances in dermatological pharmacology have revolutionized the field, expanding from basic corticosteroids to more sophisticated, targeted agents. This evolution reflects a growing understanding of the molecular mechanisms underlying skin diseases and the need for more effective, safer treatments [1].

Corticosteroids were introduced in the 1950s and quickly became the gold standard for treating inflammatory skin conditions like eczema and psoriasis. Their mechanism of action, which involves reducing inflammation and suppressing immune responses, made them highly effective. The development of various potency classes allowed for the treatment of both mild and severe conditions. Despite their success, long-term use posed risks such as skin atrophy, telangiectasia, and systemic absorption, prompting the search for alternatives [2].

In the early 2000s, topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, emerged as a valuable alternative to corticosteroids. These agents provided anti-inflammatory effects by inhibiting the activity of T-cells, which play a central role in many inflammatory skin conditions. Unlike corticosteroids, calcineurin inhibitors do not cause skin thinning, making them ideal for sensitive areas like the face and intertriginous zones. However, concerns about potential long-term cancer risks have limited their widespread adoption, though no definitive causal links have been established [3].

Topical retinoids, derivatives of vitamin A, have been a breakthrough in treating acne, photoaging, and hyperpigmentation disorders. Agents like tretinoin, adapalene, and tazarotene work by regulating cell turnover, reducing inflammation, and promoting collagen synthesis. Their ability to improve both cosmetic and medical skin issues makes them a versatile tool in dermatology. However, they are associated with side effects like irritation and photosensitivity, leading to the development of newer formulations aimed at reducing these adverse effects [4].

Fungal infections such as candidiasis and tinea have been treated with topical agents for decades. Nystatin, introduced in the 1950s, was one of the earliest antifungal treatments. In the following years, azoles like clotrimazole and miconazole became more prominent due to their broad spectrum of activity and greater efficacy. These antifungals work by inhibiting the synthesis of ergosterol, a key component of fungal cell membranes, effectively halting fungal growth. Recent developments have focused on improving delivery systems to enhance their penetration and reduce application frequency [5].

Topical antibiotics like mupirocin and fusidic acid have been instrumental in treating bacterial skin infections, including impetigo and infected eczema. Mupirocin, for example, inhibits bacterial protein synthesis, making it effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). However, the increasing emergence of antibiotic resistance has necessitated cautious use, with a focus on short-term applications to prevent resistance development [6].

With the understanding that skin diseases often involve immune dysregulation, newer agents like imiquimod and 5-fluorouracil have entered the scene. Imiquimod is an immune response modifier that boosts the skin's innate immune system, making it effective against certain skin cancers, such as basal cell carcinoma, and viral infections like genital warts. These medications represent a new wave of treatments that harness the body's natural defense mechanisms to treat skin diseases, offering a different approach compared to traditional anti-inflammatory agents [7].

The most recent advancements in topical therapy involve targeted agents that interfere with specific inflammatory pathways. Janus kinase (JAK) inhibitors, such as ruxolitinib, and phosphodiesterase-4 (PDE4) inhibitors, like crisaborole, have shown promise in treating inflammatory conditions like atopic dermatitis. These agents offer targeted anti-inflammatory effects with fewer side effects than traditional corticosteroids, marking a significant step forward in dermatology. Their ability to address the underlying immune mechanisms of skin diseases positions them as a potential game-changer in the field [8].

One of the significant challenges in dermatology has been ensuring that topical medications adequately penetrate the skin to reach their target. The advent of liposome and nanoparticle-based delivery systems has transformed the effectiveness of topical treatments. These systems encapsulate the active ingredient, allowing for better penetration, prolonged release,

***Correspondence to:** Molly Borucki, Department of Dermatology, Brown University, USA, E-mail: molly.borucki@brown.edu

***Received:** 2-Nov-2024, Manuscript No. aarcd-24-151258; **Editor assigned:** 4-Nov-2024, PreQC No. aarcd-24-151258 (PQ); **Reviewed:** 18-Nov-2024, QC No. aarcd-24-151258; **Revised**: 25-Nov-2024, Manuscript No. aarcd-24-151258 (R); **Published**: 30-Nov-2024, DOI:10.35841/aarcd-7.6.238.*

***Citation:** Borucki M. The evolution of topical medications: From corticosteroids to novel agents. Res Clin Dermatol. 2024;7(6):238.*

and reduced irritation. Drugs like corticosteroids, retinoids, and antifungals are now being formulated with these technologies, improving efficacy and patient compliance [9].

Recent interest has grown around the use of topical cannabis and cannabinoids for various dermatological conditions. Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) are believed to have anti-inflammatory and analgesic properties. Early studies suggest their potential in treating conditions like eczema, psoriasis, and pruritus. However, much of the evidence is anecdotal, and more robust clinical trials are needed to establish their efficacy and safety in dermatological use [10].

Conclusion

Despite the progress in developing new topical agents, challenges remain. The skin's barrier function limits drug absorption, and achieving the right balance between efficacy and safety is complex. Additionally, the high cost of developing novel agents and the regulatory hurdles for approval can slow down innovation. However, with ongoing research into skin biology, drug delivery technologies, and molecular targets, the future of topical medications holds promise for more effective and safer treatments.

References

1. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: Clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3:47-58.
2. Del Rosso J, Friedlander SF. Corticosteroids: Options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005;53(1):S50-8.
3. Hengge UR, Ruzicka T, Schwartz RA, et al. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-5.
4. Simpson EL. Atopic dermatitis: A review of topical treatment options. Curr Med Res Opin. 2010;26(3):633-40.
5. Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: Up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release. 2016;239:182-202.
6. Singh Malik D, Mital N, Kaur G. Topical drug delivery systems: A patent review. Expert Opin Ther Pat. 2016;26(2):213-28.
7. Prakash A, Benfield P. Topical mometasone: A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs. 1998;55:145-63.
8. Karnam S, Donthi MR, Jindal AB, et al. Recent innovations in topical delivery for management of rheumatoid arthritis: A focus on combination drug delivery. Drug Discov Today. 2024:104071.
9. K. Suresh P, K. Sah A. Patent perspectives for corticosteroids based ophthalmic therapeutics. Recent Pat Drug Deliv Formul 2014;8(3):206-23.
10. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321-7.

Citation: *Borucki M. The evolution of topical medications: From corticosteroids to novel agents. Res Clin Dermatol. 2024;7(6):238.*